What excipients does apotex's ruxolitinib formulation contain?

What excipients are in Apotex's ruxolitinib?
Apotex's ruxolitinib is a generic tablet formulation of the active ingredient ruxolitinib phosphate. The excipients listed in its product monograph include microcrystalline cellulose, magnesium stearate, and colloidal silicon dioxide.

How does this formulation differ from the brand-name Jakavi?
The brand-name Jakavi (Novartis) tablet contains lactose monohydrate, microcrystalline cellulose, and hydroxypropyl cellulose as main fillers and binders, with magnesium stearate and colloidal silicon dioxide as lubricants and glidants. The Apotex generic avoids using lactose, which may address intolerance issues for patients who are lactose intolerant.

What excipients raise patient concerns?
Patients who are lactose intolerant or have milk protein allergies avoid formulations containing lactose monohydrate. The Apotex version substitutes cellulose-based fillers instead, so it remains safe for those groups.

When will generic ruxolitinib patents expire?
Ruxolitinib patents held by Novartis are scheduled to expire in 2024.